High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers

International Journal of Pharmaceutics

Volumn 361, Issue 1-2, 2008, Pages 177-188

  Yang, Wei ^a   Tam, Jasmine ^b   Miller, Dave A ^a   Zhou, Jiping ^b   McConville, Jason T ^a   Johnston, Keith P ^b   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b The University of Texas at Austin   (United States)

Author keywords

Amorphous; Antifungal; Aspergillosis; Bioavailability; Poorly water soluble drug; Solid solution

Indexed keywords

ITRACONAZOLE; MANNITOL; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; STABILIZING AGENT;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COLLOID; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; EXCIPIENT COMPATIBILITY; FREEZING; IN VIVO STUDY; LUNG FLUID; MALE; MOUSE; NEBULIZATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SIMULATION; SURFACE PROPERTY; X RAY POWDER DIFFRACTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; FREEZING; HALF-LIFE; ITRACONAZOLE; LECITHINS; LUNG; MALE; MANNITOL; MICE; MICE, INBRED ICR; NANOPARTICLES; PERMEABILITY; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 47949098294     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.05.003     Document Type: Article

References (74)

1. Adje A.L., and Gupta P.K. Inhalation delivery of therapeutic peptides and proteins. In: Mahmoud A.A.F. (Ed). Parasitic Lung Diseases (1997), Marcel Rcel Dekker Inc., New York 89-125
2. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
3. Barone J.A., Koh J.G., Bierman R.H., Colaizzi J.L., Swanson K.A., Gaffar M.C., Moskovitz B.L., Mechlinski W., and Vandevelde V. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male-volunteers. Antimicrob. Agents Chemother. 37 (1993) 778-784
4. Bernhard W., Haagsman H.P., Tschernig T., Poets C.F., Postle A.D., Vaneijk M.E., and Vonderhardt H. Conductive airway surfactant: surface-tension function, biochemical composition, and possible alveolar origin. Am. J. Respir. Cell Mol. Biol. 17 (1997) 41-50
5. Betageri G.V., and Makarla K.R. Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques. Int. J. Pharm. 126 (1995) 155-160
6. Bosquillon C., Lombry C., Preat V., and Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release 70 (2001) 329-339
7. Byron P., and Phillips E. In: Byron P.R. (Ed). Absorption, Clearance and Dissolution in the Lung (1990), Respiratory Drug Delivery CRC, Boca Raton, FL 107-141
8. Chan H.K., and Gonda I. Development of a systematic theory of suspension inhalation aerosols. 2. Aggregates of monodisperse particles nebulized in polydisperse droplets. Int. J. Pharm. 41 (1988) 147-157
9. Chiou W.L. Pharmaceutical applications of solid dispersion systems: X-ray diffraction and aqueous solubility studies on griseofulvin-polyethylene glycol 6000 systems. J. Pharm. Sci. 66 (1977) 989-991
10. Chow A.H.L., Tong H.H.Y., Chattopadhyay P., and Shekunov B.Y. Particle engineering for pulmonary drug delivery. Pharm. Res. 24 (2007) 411-437
11. Clark T.A., and Hajjeh R.A. Recent trends in the epidemiology of invasive mycoses. Curr. Opin. Infect. Dis. 15 (2002) 569-574
12. Codrons V., Vanderbist F., Ucakar B., Preat V., and Vanbever R. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J. Pharm. Sci. 93 (2004) 1241-1252
13. Cook R.O., Pannu R.K., and Kellaway I.W. Novel sustained release microspheres for pulmonary drug delivery. J. Control. Release 104 (2005) 79-90
14. Courrier H.M., Butz N., and Vandamme T.F. Pulmonary drug delivery systems: recent developments and prospects. Crit. Rev. Ther. Drug Carrier Syst. 19 (2002) 425-498
15. Crisp M.T., Tucker C.J., Rogers T.L., Williams R.O., and Johnston K.P. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. J. Control. Release 117 (2007) 351-359
16. Damian F., Blaton N., Naesens L., Balzarini J., Kinget R., Augustijns P., and Van Den Mooter G. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. Eur. J. Pharm. Sci. 10 (2000) 311-322
17. Davies N.M., and Feddah M.R. A novel method for assessing dissolution of aerosol inhaler products. Int. J. Pharm. 255 (2003) 175-187
18. Ebbesen M., and Jensen T.G. Nanomedicine: techniques, potentials, and ethical implications. J. Biomed. Biotechnol. 2006 (2006) 51516
19. Edwards D.A., and Dunbar C. Bioengineering of therapeutic aerosols. Annu. Rev. Biomed. Eng. 4 (2002) 93-107
20. Engstrom J.D., Lai E.S., Ludher B.S., Chen B., Milner T.E., Williams III R.O., Kitto G.B., and Johnston K.P. Formation of stable submicron protein particles by thin film freezing. Pharm. Res. 25 (2008) 1334-1346
21. Evans J.C., Scherzer B.D., Tocco C.D., Kupperblatt G.B., Becker J.N., Wilson D.L., Saghir S.A., and Elder E.J. Preparation of nanostructured particles of poorly water soluble drugs via a novel ultra-rapid freezing technology. In: Svenson S. (Ed). Polymeric Drug Delivery-Polymeric Matrices and Drug Particle Engineering, ACS Symposium Series 924 (2006), American Chemical Society, Washington, DC 320-328
22. Forbes B., and Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. Eur. J. Pharm. Biopharm. 60 (2005) 193-205
23. Geelhaar A., and Weibel E.R. Morphometric estimation of pulmonary diffusion capacity. 3. The effect of increased oxygen consumption in Japanese Waltzing mice. Respir. Physiol. 11 (1971) 354-366
24. Goerke J. Pulmonary surfactant: functions and molecular composition. Biochim. Biophys. Acta 1408 (1998) 79-89
25. Hancock B.C., and Parks M. What is the true solubility advantage for amorphous pharmaceuticals?. Pharm. Res. 17 (2000) 397-404
26. Hu J., Johnston K.P., and Williams III R.O. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug. Dev. Ind. Pharm. 30 (2004) 233-245
27. Jacobs C., and Muller R.H. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 19 (2002) 189-194
28. Kapsi S.G., and Ayres J.W. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. Int. J. Pharm. 229 (2001) 193-203
29. Kim A.I., Akers M.J., and Nail S.L. The physical state of mannitol after freeze-drying: effects of mannitol concentration, freezing rate, and a noncrystallizing cosolute. J. Pharm. Sci. 87 (1998) 931-935
30. Leuner C., and Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50 (2000) 47-60
31. Lin S.J., Schranz J., and Teutsch S.M. Aspergillosis case - fatality rate: systematic review of the literature. Clin. Infect. Dis. 32 (2001) 358-366
32. Lindmark T., Kimura Y., and Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther. 284 (1998) 362-369
33. Liu F.Y., Shao Z., Kildsig D.O., and Mitra A.K. Pulmonary delivery of free and liposomal insulin. Pharm. Res. 10 (1993) 228-232
34. Lum H., and Mitzner W. A species comparison of alveolar size and surface forces. J. Appl. Physiol. 62 (1987) 1865-1871
35. Martin A. Physical Pharmacy. Fourth ed. (1993), Williams &Wilkins, Baltimore
36. Matteucci M.E., Brettmann B.K., Rogers T.L., Elder E.J., Williams III R.O., and Johnston K.P. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Mol. Pharm. 4 (2007) 782-793
37. Mawson S., Yates M.Z., Oneill M.L., and Johnston K.P. Stabilized polymer microparticles by precipitation with a compressed fluid antisolvent. 2. Poly(propylene oxide)- and poly(butylene oxide)-based copolymers. Langmuir 13 (1997) 1519-1528
38. Mccabe W.L., Smith J.C., and Harriott P. Unit Operations of Chemical Engineering (2001), McGraw Hill Inc., Boston, MA
39. Mccallion O.N., Taylor K.M., Thomas M., and Taylor A.J. Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm. Res. 12 (1995) 1682-1688
40. McConville J.T., Williams R.O., Carvalho T.C., Iberg A.N., Johnston K.P., Talbert R.L., Burgess D., and Peters J.I. Design and evaluation of a restraint-free small animal inhalation dosing chamber. Drug Dev. Ind. Pharm. 31 (2005) 35-42
41. McConville J.T., Overhoff K.A., Sinswat P., Vaughn J.M., Frei B.L., Burgess D.S., Talbert R.L., Peters J.I., Johnston K.P., and Williams III R.O. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm. Res. 23 (2006) 901-911
42. Mehrad B., Paciocco G., Martinez F.J., Ojo T.C., Iannettoni M.D., and Lynch III J.P. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 119 (2001) 169-175
43. Mitra R., Pezron I., Li Y., and Mitra A.K. Enhanced pulmonary delivery of insulin by lung lavage fluid and phospholipids. Int. J. Pharm. 217 (2001) 25-31
44. Myers M.A., Thomas D.A., Straub L., Soucy D.W., Niven R.W., Kaltenbach M., Hood C.I., Schreier H., and Gonzalez-Rothi R.J. Pulmonary effects of chronic exposure to liposome aerosols in mice. Exp. Lung Res. 19 (1993) 1-19
45. Niven R.W. Pharmaceutical Inhalation Aerosol Technology (1992), Marcel Dekker, Inc., New York
46. Ostrander K.D., Bosch H.W., and Bondanza D.M. An in-vitro assessment of a nanocrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur. J. Pharm. Biopharm. 48 (1999) 207-215
47. Ott P., Hope M.J., Verkleij A.J., Roelofsen B., Brodbeck U., and Van Deenen L.L. Effect of dimyristoyl phosphatidylcholine on intact erythrocytes. Release of spectrin-free vesicles without ATP depletion. Biochim. Biophys. Acta 641 (1981) 79-87
48. Overhoff K.A., Engstrom J.D., Chen B., Scherzer B.D., Milner T.E., Johnston K.P., and Williams III R.O. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 65 (2007) 57-67
49. Overhoff K.A., Moreno A., Miller D.A., Johnston K.P., and Williams III R.O. Solid dispersions of itraconazole and enteric polymers made by ultra-rapid freezing. Int. J. Pharm. 336 (2007) 122-132
50. Patton J. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Del. Rev. 19 (1996) 3-36
51. Patton J.S., and Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 6 (2007) 67-74
52. Patton J.S., Mccabe J.G., Hansen S.E., and Daugherty A.L. Absorption of human growth hormone from the rat lung. Biotechnol. Ther. 1 (1989) 213-228
53. Peeters J., Neeskens P., Tollenaere J.P., Van Remoortere P., and Brewster M.E. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4 and 7. J. Pharm. Sci. 91 (2002) 1414-1422
54. Poirier J.M., Hardy S., Isnard F., Tilleul P., Weissenburger J., and Cheymol G. Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen. Ther. Drug Monit. 19 (1997) 525-529
55. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3 (2004) 785-796
56. Roelofsen B., Kuypers F.A., Op Den Kamp J.A., and Van Deenen L.L. Influence of phosphatidylcholine molecular species composition on stability of the erythrocyte membrane. Biochem. Soc. Trans. 17 (1989) 284-286
57. 2 and cryogenic spray-freezing technologies. Drug Dev. Ind. Pharm. 27 (2001) 1003-1015
58. Rowland M., and Tozer T. Absorption and disposition kinetics. In: Rowland M., and Tozer T. (Eds). Clinical Pharmacokinetics: Concepts and Applications. third ed. (1995), Lippincott Williams & Wilkins, Baltimore 11-52
59. Sarkari M., Brown J., Chen X., Swinnea S., Williams III R.O., and Johnston K.P. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int. J. Pharm. 243 (2002) 17-31
60. Sarver L.W. SEM and EDS analyze materials. Adv. Mater. Process. 150 (1996) 19-21
61. Singh N., and Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J. Heart Lung Transplant. 22 (2003) 258-266
62. Six K., Verreck G., Peeters J., Augustijns P., Kinget R., and Van Den Mooter G. Characterization of glassy itraconazole: a comparative study of its molecular mobility below T(g) with that of structural analogues using MTDSC. Int. J. Pharm. 213 (2001) 163-173
63. Smith D., Van De Velde V., Woestenborghs R., and Gazzard B.G. The pharmacokinetics of oral itraconazole in AIDS patients. J. Pharm. Pharmacol. 44 (1992) 618-619
64. Sobel J.D. Practice guidelines for the treatment of fungal infections. For the Mycoses Study Group. Infectious Diseases Society of America. Clin. Infect. Dis. 30 (2000) 652
65. Tam J., Mcconville J.T., Williams III R.O., and Johnston K.P. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J. Pharm. Sci. (2008) 10.1002/jps.21367
66. Tinke A.P., Vanhoutte K., De Maesschalck R., Verheyen S., and De Winter H. A new approach in the prediction of the dissolution behavior of suspended particles by means of their particle size distribution. J. Pharm. Biomed. Anal. 39 (2005) 900-907
67. Van Den Mooter G., Wuyts M., Blaton N., Busson R., Grobet P., Augustijns P., and Kinget R. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur. J Pharm. Sci. 12 (2001) 261-269
68. Van Drooge D.J., Hinrichs W.L., and Frijlink H.W. Anomalous dissolution behaviour of tablets prepared from sugar glass-based solid dispersions. J. Control. Release 97 (2004) 441-452
69. Varma M.V., Sateesh K., and Panchagnula R. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol. Pharm. 2 (2005) 12-21
70. Vaughn J.M., Gao X., Yacaman M.J., Johnston K.P., and Williams III R.O. Comparison of powder produced by evaporative precipitation into aqueous solution (EPAS) and spray freezing into liquid (SFL) technologies using novel Z-contrast STEM and complimentary techniques. Eur. J. Pharm. Biopharm. 60 (2005) 81-89
71. Vaughn J.M., Mcconville J.T., Burgess D., Peters J.I., Johnston K.P., Talbert R.L., and Williams III R.O. Single dose and multiple dose studies of itraconazole nanoparticles. Eur. J. Pharm. Biopharm. 63 (2006) 95-102
72. Verreck G., Six K., Van Den Mooter G., Baert L., Peeters J., and Brewster M.E. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion-Part I. Int. J. Pharm. 251 (2003) 165-174
73. Yamashita K., Nakate T., Okimoto K., Ohike A., Tokunaga Y., Ibuki R., Higaki K., and Kimura T. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm. 267 (2003) 79-91
74. Yang W., Peters J.I., and Williams III R.O. Inhaled nanoparticles-a current review. Int. J. Pharm. 356 (2008) 239-247